Table 2.
Descriptive statistics and univariable analysis.
| HR (95% CI) | p | |
|---|---|---|
| Graft factor | ||
| Donor age (years) | 0.99 (0.95–1.03) | 0.550 |
| Male donor | 1.78 (0.70–4.56) | 0.230 |
| Graft-to-recipient weight ratio < 1.0% | 0.48 (0.22–1.07) | 0.071 |
| Macrosteatosis ≥ 5% | 0.89 (0.42–1.90) | 0.770 |
| Cold ischemia time (minutes) | 0.99 (0.98–1.01) | 0.320 |
| Recipient factors | ||
| Age (years) | 1.02 (0.95–1.09) | 0.680 |
| Male | — | — |
| Body mass index (kg/m2) | 0.84 (0.74–0.96) | 0.010 |
| Diagnosed diabetes | 1.09 (0.51–2.34) | 0.820 |
| MELD score ≥ 20 | 0.87 (0.26–2.87) | 0.820 |
| Sodium level (mmol/L) | 1.06 (0.98–1.14) | 0.160 |
| Hepatic encephalopathy | ||
| None | ||
| Grade I-II (vs. none) | 0.83 (0.25–2.75) | 0.757 |
| Grade III–IV | 0 | — |
| Refractory ascites | 0.52 (0.16–1.65) | 0.260 |
| Pretransplant CRRT | — | — |
| Pretransplant tumor treatment history | 3.92 (0.90–17.01) | 0.068 |
| High sensitive C-reactive protein (mg/L) | 1.06 (0.92–1.22) | 0.419 |
| Neutrophil-to-lymphocyte ratio | 1.03 (0.90–1.17) | 0.680 |
| Sarcopenia | 8.06 (1.06–16.7) | 0.044 |
| Surgical factors | ||
| Operative time >10 hours | 0.57 (0.25–1.31) | 0.190 |
| Perioperative RBC transfusion > 6 units | 0.52 (0.20–1.35) | 0.180 |
| Tacrolimus trough concentration > 10 ng/mL | 2.14 (0.99–4.62) | 0.054 |
| Tumor biology | ||
| AFP (log-transformed ng/mL)* | 1.30 (1.12–1.52) | 0.001 |
| Tumor number | ||
| Solitary | ||
| 2–3 (vs. solitary) | 0.89 (0.16–5.05) | 0.890 |
| >3 (vs. solitary) | 1.55 (0.34–7.09) | 0.570 |
| Tumor size* | 1.25 (1.14–1.37) | <0.001 |
| Microvascular invasion | 5.05 (1.80–14.19) | 0.002 |
| Bile duct invasion | 2.34 (0.70–7.86) | 0.168 |
| Edmonson grade III–IV (vs. grade I–II) | 2.03 (0.56–7.29) | 0.280 |
| Non-tumor liver cirrhosis | 0.50 (0.19–1.34) | 0.170 |
Data are presented as median (25th percentile, 75th percentile) or frequency (percent). Sarcopenia was defined based on transverse psoas muscle thickness. AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; RBC, red blood cell. CRRT, continuous renal replacement therapy. *Hazard ratios and P values were calculated for log-transformed values due to skewed distribution.